FDA Approves Jazz Pharmaceuticals' Ziihera for First-Line HER2+ Gastroesophageal Cancer — Jazz Pharmaceuticals plc

Event summary

FDA approved Ziihera (zanidatamab-hrii) for first-line treatment of HER2+ gastroesophageal adenocarcinoma (GEA) in two regimens: with tislelizumab and chemotherapy, and with chemotherapy alone.
The approval is based on Phase 3 HERIZON-GEA-01 trial results showing median overall survival of 26.4 months, the longest reported in a Phase 3 trial for this indication.
Ziihera is the first and only bispecific HER2-targeted antibody combined with a PD-1 inhibitor and chemotherapy approved for all HER2+ advanced GEA patients, regardless of PD-L1 status.
The trial demonstrated a 28% reduction in the risk of death compared to trastuzumab plus chemotherapy.

The big picture

This approval positions Ziihera as a potential new standard of care for HER2+ GEA, a cancer type with high morbidity and mortality. The approval is significant given the longest median overall survival reported in a Phase 3 trial for this indication. Jazz Pharmaceuticals is leveraging this success to pursue additional regulatory approvals for zanidatamab in other markets and indications, expanding its portfolio in the oncology space.

What we're watching

Market Penetration: Whether Jazz Pharmaceuticals can establish Ziihera as the new standard of care in first-line HER2+ GEA treatment.
Regulatory Strategy: The pace at which Jazz Pharmaceuticals pursues additional regulatory approvals for zanidatamab in other markets.
Clinical Development: The outcomes of ongoing and additional analyses from the HERIZON-GEA-01 trial and other zanidatamab development programs.